XPyto pursues potential application of its oral soluble biosensor inflammation assay for buprenorphine-related dental disease


VANCOUVER, BC and UTTENWEILER, GERMANY/ACCESSWIRE/July 18, 2022/XPyto Therapeutics Corp. (CSE: XPHY), (OTCQB: XPHYF), (FSE: 4XT) (“XPyto” or the “Company”) is pleased to announce a significant potential market opportunity for its oral soluble biosensor (“ODF”) assays screening for oral inflammation. Certain buprenorphine medications prescribed to treat opioid use disorder (“OUD”) and pain have recently been associated with many serious oral health conditions requiring medical intervention. Buprenorphine is a drug approved by the United States Food and Drug Administration (the “FDA”) to treat OUD as a drug treatment (MAT). The number of American adolescents and adults with OUD in 2019 was estimated to be between 6.7 and 7.6 million. XPyto is investigating the potential application of one or more of its ODF biosensor screening assays for oral inflammation to detect buprenorphine-related dental problems.

This year, the FDA issued a Drug Safety Communication (“DSC”) titled “FDA warns of dental problems with buprenorphine drugs dissolved in the mouth to treat drug use disorders of opioids and pain”. The DSC notes that dental problems include “tooth decay, cavities, oral infections and tooth loss, can be serious and have been reported even in patients with no history of dental problems”. Despite the severity of the side effects, the FDA recommends continued use of these medications because the benefits outweigh the risks, and oral care may help. The global buprenorphine market is expected to surpass US$10.9 billion by 2027 according to Coherent Market Insights (CMI).

XPyto’s proprietary ODF biosensor development portfolio includes several oral health products, including for the detection of stomatitis, periodontitis and peri-implantitis. The company’s first ODF biosensor screening product is for general oral inflammation. Positive detection of causative inflammatory agents results in an enzymatic release of a bitter compound into the mouth of the user, with no medical training, testing equipment, or power supply required. The Oral Inflammation Biosensor is designed to function as a simple, inexpensive, self-administered screening test to identify users for follow-up medical testing. The company’s soluble oral inflammation screening test was registered in the EU in late 2021 and is currently cleared for marketing and sale in Europe.

The Company is currently investigating the potential application of one or more of its oral health biosensor screening tests for the detection of buprenorphine-related dental problems. Clinical evaluation requirements for commercial registration and/or approval will be published once established. The company plans to provide further updates on its oral health and infectious disease screening programs in the coming weeks.

XPyto’s biosensor screening product portfolio for inflammatory, bacterial and viral infectious diseases includes stomatitis, peri-implantitis, periodontitis, group A streptococcus, influenza A and covid-19. This suite of biosensor products positions the company in the global biosensor and oral health markets which are expected to reach US$42 billion by 2027 according to Global Market Insights and e-magazine MedicalExpo and are expected to reach US$698.8 billion. US dollars by 2030.

About XPyto Therapeutics Corp.
XPyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostics and new investment opportunities in active pharmaceutical ingredients, including: precision transdermal and oral soluble drug formulations; rapid and inexpensive diagnostic tests for infectious diseases and oral health; and the manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological disorders. The Company has research and development activities in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

X Phyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Email: [email protected]
Telephone: +1 780-818-642

Raimar Löbenberg, PhD
Director, Center for Drug Development and Innovation
Faculty of Pharmacy and Pharmaceutical Sciences
Group Katz-Rexall Center for Pharmacy & Health Research
University of Alberta
11315 – 87 Avenue, room 3-142-K
Edmonton, AB T6G 2T9
Call: 780 492 1255
Fax: 780 492 1217
Skype: Raimarloebenberg

Forward-looking statements
This press release contains statements that contain forward-looking information within the meaning of applicable Canadian securities laws (“forward-looking statements”). Forward-looking statements are often characterized by words such as “develop”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potential”, “propose” and other similar words or statements that certain events or conditions “may” or “will” occur, and in this release include the statement regarding the company’s purpose to build a successful diagnostics, drug distribution and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management as of the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results differ materially from those projected in the forward-looking statements, including: that the Company may not be successful in developing a commercial product; that selling products may not be a viable business; that the Company may not be able to expand its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources and/or inability to access sufficient capital on favorable terms; currency risks; competition; international risks; and other risks beyond the Company’s control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. expressly requires. Neither the CSE nor its Market Regulator (as that term is defined in the CSE policies) accepts responsibility for the adequacy or accuracy of this press release.

THE SOURCE: X Phyto Therapeutics Corp.

See the source version on accesswire.com:


About Author

Comments are closed.